欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (1): 56-58.

• 研究原著 • 上一篇    下一篇

诺司咪唑抗过敏作用的实验研究

刘昌孝, 王瑞芝, 刘宁, 李晶, 程晓翔   

  1. 天津药物研究院新药评价研究中心, 天津 300193
  • 收稿日期:2003-08-24 修回日期:2003-09-27 出版日期:2004-01-26 发布日期:2020-11-16
  • 通讯作者: 刘昌孝,男, 研究员,博士导师, 从事药物代谢与动力学研究。Tel Fax:022-23006863  E-mail: cxliutj@hotmail.com
  • 作者简介:王瑞芝, 女, 本科, 副研究员, 主要从事药理药效学研究。Tel:23006867 E-mail:wl300193@eyou.com

Experiment study on antiallergic effects of norstemizole

LIU Chang-Xiao, WANG Rui-Zhi, LIU Ning, LI Jing, CHENG Xiao-Xiang   

  1. Department of Pharmacology, Tianjin Research Institute of Medicine, Tianjin 300193, China
  • Received:2003-08-24 Revised:2003-09-27 Online:2004-01-26 Published:2020-11-16

摘要: 目的: 观察诺司咪唑(norstemizole)的抗过敏作用。方法: 采用豚鼠在体和离体实验模型, 观察诺司咪唑的抗过敏效应。结果: 诺司咪唑10-9~10-8 mol·L-1, 能抑制磷酸组胺引起的豚鼠离体回肠平滑肌的收缩, IC50为4.42 ×10-9 mol·L-1 。豚鼠口服诺司咪唑0.1, 0.5 和1.0 mg·kg-1 3 个剂量, 均可显著地抑制磷酸组胺所致的休克作用和皮肤血管通透性增加(P<0.01)。在大鼠同种被动皮肤过敏(PCA)模型中, 能显著地抑制其皮肤过敏, 抑制率分别为23.6 %, 67.9 %和81.7 %。结论: 诺司咪唑为第三代抗组胺药, 在药效上优于母体化合物阿司咪唑。

关键词: 诺司咪唑, 抗过敏, 磷酸组胺, 豚鼠离体回肠, 通透性

Abstract: AIM: To study the antiallerergic effects of norastemizole.METHODS: Antiallergic effects of norastemizole were study using rats and guinea pigs.RESULTS: Norastemizole (10-9-10-8 mol·L-1) caused inhibition effect on the hisitamine-induced contraction of isolated guinea pig ileum.Its IC50 was 4.42 ×10-9mol·L-1.Norastemizole at oral doses of 0.1, 0.5,1 mg·kg-1, norastemizole caused a significant inhibition on the histamin-phosphate induced shock in guinea pigs (P<0.01).At doses of 0.5, 1.0 and 2.0 mg·kg-1, it significantly inhibited homologous PCA (P<0.01).At oral doses of 0.05, 0.5 and 1.0 mg·kg-1, norastemizole caused a significant inhibition on the increase of skin vascular permeability induced by histamine.CONCLUSION: Norastemizole is a third-generation antihistamine drug, and shows significant advantages over the parent compound astemizole in potency.

Key words: norastemizol, antiallergic, histame-phosphate, isolated guinea pig ileum, permeability

中图分类号: